A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Public ClinicalTrials.gov record NCT01629667. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.
Study identification
- NCT ID
- NCT01629667
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 409 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2012 (Type not available)
- Primary completion
- May 2015 (Actual)
- Completion
- Jan 2016 (Actual)
- Last update posted
- May 15, 2017
2012 – 2016
United States locations
- U.S. sites
- 21
- U.S. states
- 17
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | — | — |
| Research Site | La Jolla | California | — | — |
| Research Site | Sacramento | California | — | — |
| Research Site | Tampa | Florida | — | — |
| Research Site | Winter Park | Florida | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Honolulu | Hawaii | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Louisville | Kentucky | — | — |
| Research Site | Ann Arbor | Michigan | — | — |
| Research Site | Rochester | Minnesota | — | — |
| Research Site | Chesterfield | Missouri | — | — |
| Research Site | Summit | New Jersey | — | — |
| Research Site | Durham | North Carolina | — | — |
| Research Site | Hershey | Pennsylvania | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Charleston | South Carolina | — | — |
| Research Site | Nashville | Tennessee | — | — |
| Research Site | McAllen | Texas | — | — |
| Research Site | McKinney | Texas | — | — |
| Research Site | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01629667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2017 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01629667 live on ClinicalTrials.gov.